A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
Stopped Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.
Conditions
- Acute Antibody-Mediated Rejection (AMR)
Interventions
- BIOLOGICAL: Cinryze®
- DRUG: Placebo
Sponsor
Shire